FDA panel proposes new limitations on Amgen, J&J anemia drugs

03/13/2008 | Wall Street Journal (free content), The · CNNMoney

An FDA advisory panel on Thursday voted to keep anemia drugs from Johnson & Johnson and Amgen on the market for use in cancer patients but suggested revisions to their safety labels. The committee ruled that the drugs, marketed as Procrit by J&J and Epogen and Aranesp by Amgen, should not be given to people with advanced breast cancer and head-and-neck cancer. J&J said it was "concerned" by the recommendations, while Amgen said it will coordinate with the agency to address the proposed limitations.

View Full Article in:

Wall Street Journal (free content), The · CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN